Literature DB >> 25401689

Biologic therapy in lupus nephritis.

Frédéric A Houssiau1.   

Abstract

This position paper critically analyzes the available controlled data regarding biologic therapy in lupus nephritis (LN). Rather than an exhaustive review of all published evidence, the stress is put on the unmet medical needs in LN, the design of trials aimed at testing the effect of a biologic in LN, the possible reasons for LN trial failures and the future of biological therapy in LN.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25401689     DOI： 10.1159/000368587

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN： 1660-2110


  6 in total

Review 1.  A systems approach to renal inflammation in SLE.

Authors:  Celine C Berthier; Matthias Kretzler; Anne Davidson
Journal:  Clin Immunol       Date:  2016-08-14       Impact factor: 3.969

Review 2.  Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy.

Authors:  Naomi I Maria; Anne Davidson
Journal:  Nat Rev Rheumatol       Date:  2020-03-19       Impact factor: 20.543

Review 3.  What is damaging the kidney in lupus nephritis?

Authors:  Anne Davidson
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

4.  Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.

Authors:  Farah Tamirou; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Christoph Fiehn; Maria del Mar Ayala Guttierez; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera; Frédéric A Houssiau
Journal:  Ann Rheum Dis       Date:  2015-03-10       Impact factor: 19.103

5.  Systematic identification of key extracellular proteins as the potential biomarkers in lupus nephritis.

Authors:  Xue Zhou; Yuefeng Zhang; Ning Wang
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

6.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Authors:  Brad H Rovin; Ronald F van Vollenhoven; Cynthia Aranow; Carrie Wagner; Robert Gordon; Yanli Zhuang; Stanley Belkowski; Benjamin Hsu
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.